Fig. 1From: Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional reviewKaplan–Meier estimates of overall survival. The primary efficacy measure in the present study assessed overall survival, which was calculated as the time from diagnosis of metastatic breast cancer until death from any cause. HR denotes hazard ratio for the eribulin arm as compared with the noneribulin armBack to article page